Santen Pharmaceutical Co (JP:4536) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Santen Pharmaceutical Co., Ltd has reported a modest revenue increase of 3.3% for the three months ending June 30, 2024, compared to the same period last year. However, there has been a slight decrease in core net profit by 2.1%. The company has also announced a share repurchase program, which is expected to impact their earnings per share forecasts.
For further insights into JP:4536 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue